Biohaven Pharmaceutical Holding Company Ltd. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Biohaven Pharmaceutical Holding Company Ltd. reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of $125.74 million for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-05.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2022-08-05
- Biohaven Pharmaceutical Holding Company Ltd. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2022-06-30 was $77.08M.
- Biohaven Pharmaceutical Holding Company Ltd. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2022-03-31 was $48.66M, a 1.56% increase year-over-year.
- Biohaven Pharmaceutical Holding Company Ltd. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2021-12-31 was $51.51M, a 80.08% increase year-over-year.
- Biohaven Pharmaceutical Holding Company Ltd. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2021-09-30 was $26.22M.
- Biohaven Pharmaceutical Holding Company Ltd. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2021 was $113.46M, a 22.76% increase from fiscal 2020.
- Biohaven Pharmaceutical Holding Company Ltd. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2020 was $92.42M, a 113.35% increase from fiscal 2019.
- Biohaven Pharmaceutical Holding Company Ltd. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2019 was $43.32M.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2022-06-30 | $77.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $125.74M 10-Q · filed 2022-08-05 | $177.25M derived: sum of 3 quarters · filed 2022-08-05 | $203.47M derived: sum of 4 quarters · filed 2022-08-05 |
| 2022-03-31 | $48.66M 10-Q · filed 2022-05-10 | $100.17M derived: sum of 2 quarters · filed 2022-05-10 | $126.39M derived: sum of 3 quarters · filed 2022-05-10 | $114.20M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-12-31 | $51.51M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $77.73M derived: sum of 2 quarters · filed 2022-02-25 | $65.54M derived: sum of 3 quarters · filed 2022-08-05 | $113.46M 10-K · filed 2022-02-25 |
| 2021-09-30 | $26.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $14.04M derived: sum of 2 quarters · filed 2022-08-05 | $61.95M 10-Q · filed 2021-11-09 | $90.55M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-06-30 | -$12.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $35.73M 10-Q · filed 2022-08-05 | $64.33M derived: sum of 3 quarters · filed 2022-08-05 | |
| 2021-03-31 | $47.91M 10-Q · filed 2022-05-10 | $76.52M derived: sum of 2 quarters · filed 2022-05-10 | ||
| 2020-12-31 | $28.60M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $92.42M 10-K · filed 2022-02-25 | ||
| 2020-09-30 | $63.82M 10-Q · filed 2021-11-09 | |||
| 2019-12-31 | $43.32M 10-K · filed 2022-02-25 |